Envestnet Portfolio Solutions
BMRN icon

Envestnet Portfolio Solutions’s BioMarin Pharmaceuticals BMRN Stock Holding History

Envestnet Portfolio Solutions’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,388
Closed -$223K – 1568
2024
Q4 		$223K Sell
3,388
-430
-11% -$28.8K ﹤0.01% 1636
2024
Q3 		$268K Buy
3,818
+431
+13% +$36K ﹤0.01% 1506
2024
Q2 		$279K Sell
3,387
-7,281
-68% -$606K ﹤0.01% 1417
2024
Q1 		$932K Buy
10,668
+130
+1% +$11.6K ﹤0.01% 864
2023
Q4 		$1.02M Buy
10,538
+917
+10% +$81.1K ﹤0.01% 790
2023
Q3 		$851K Buy
+9,621
New +$856K ﹤0.01% 791

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
EIM
Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Envestnet Portfolio Solutions's BMRN Position: Q1 2025 in Review

Envestnet Portfolio Solutions sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2025, closing a stake of 3,388 shares — an estimated $223K sold.

Envestnet Portfolio Solutions first reported a position in BMRN in Q3 2023 and held it in 6 quarters. The position peaked at $1.02M in Q4 2023. 584 funds tracked by Wall St. Rank hold BMRN as of Q1 2025.

  • Envestnet Portfolio Solutions reported no remaining BioMarin Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Envestnet Portfolio Solutions sold 3,388 BioMarin Pharmaceuticals shares in Q1 2025, an estimated $223K.
  • Envestnet Portfolio Solutions first reported a position in BioMarin Pharmaceuticals in Q3 2023 and held it in 6 quarters.
  • Envestnet Portfolio Solutions's BioMarin Pharmaceuticals position peaked at $1.02M in Q4 2023.
  • 584 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2025.

Based on Envestnet Portfolio Solutions's 13F filing for Q1 2025, filed 21 Apr 2025.